PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Quotes for PharmaLundensis AB

Right Now

+/-
0.058
%
9,97%
Latest
0.64
High
0.644
Low
0.602
Volume
8 701
Turnover (SEK)
5 571
Market Value (MSEK)
27,2
Time (Latest trade)

Board

CEO

  • Staffan Skogvall

Chairperson of the Board

  • Arne Skogvall

Board

  • Bo Wennergren
  • Björn Sivik
  • Staffan Skogvall
  • Stefan Ahlfors

Largest Owners

Name Capital % Votes % Date
Staffan Skogvall 50,64 50,64 2024-06-26
Vict Th Engwalls Stiftelse 2,29 2,29 2024-06-26
Avanza Pension 1,50 1,50 2024-06-26
Arne Arvidsson 1,43 1,43 2024-06-26
Nordnet Pensionsförsäkring 0,80 0,80 2024-06-26
Tommy Johansson 0,71 0,71 2024-06-26
Staffan Engelbert Bodén 0,62 0,62 2024-06-26
Magnus Persson 0,55 0,55 2024-06-26
Merrick Lee Tabor 0,53 0,53 2024-06-26
Arne Skogvall 0,52 0,52 2024-06-26
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2024-08-15 Delårsrapport 2024-Q2

  • 2024-11-21 Delårsrapport 2024-Q3

  • 2025-02-20 Bokslutskommuniké 2024